Literature DB >> 25194851

Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.

Yu-Qiang Mi1, Qi-Yu Shi, Liang Xu, Rui-Fang Shi, Yong-Gang Liu, Ping Li, Feng Shen, Wei Lu, Jian-Gao Fan.   

Abstract

BACKGROUND AND AIM: The controlled attenuation parameter (CAP) using transient elastography (TE) was validated in chronic hepatitis C to evaluate hepatic steatosis; however, limited data are available on chronic hepatitis B (CHB). Therefore, we assessed the accuracy and the efficacy of CAP for the detection of steatosis in CHB.
METHODS: Consecutive CHB patients underwent liver biopsy and liver stiffness measurements (LSM) with simultaneous CAP determination using the M probe of the TE. The area under the receiver operating characteristics curve (AUROC) was used to evaluate the performance of CAP in diagnosing steatosis compared with biopsy.
RESULTS: A total of 340 patients were included: 60 % were male, the median age was 37 years; the body mass index (BMI) was ≥ 28 kg/m(2) for 14 % of the subjects; and the distribution of the steatosis grade was S0 58.2 %, S1 34.2 %, S2 5.0 % and S3 2.6 %. The median (range) of CAP was 218 (100-400) dB/m, and CAP correlated with the BMI (ρ = 3.622) and steatosis grade (ρ = 29.203) according to a multivariate analysis (both P < 0.001). CAP could detect the different grades of steatosis: ≥ S1 with AUROC of 0.81 at a cutoff of 224 dB/m, ≥ S2 with AUROC of 0.90 at a cutoff of 236 dB/m and ≥ S3 with AUROC of 0.97 at a cutoff of 285 dB/m. Furthermore, the LSM and fibrosis and activity grades on biopsy did not influence the CAP performance.
CONCLUSIONS: CAP presented excellent diagnostic performance for severe steatosis with high sensitivity and specificity in Chinese patients with CHB.

Entities:  

Mesh:

Year:  2014        PMID: 25194851     DOI: 10.1007/s10620-014-3341-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  44 in total

1.  Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.

Authors:  M Sasso; I Tengher-Barna; M Ziol; V Miette; C Fournier; L Sandrin; R Poupon; A-C Cardoso; P Marcellin; C Douvin; V de Ledinghen; J-C Trinchet; M Beaugrand
Journal:  J Viral Hepat       Date:  2011-10-13       Impact factor: 3.728

Review 2.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

3.  Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.

Authors:  Laurentius A Lesmana; C Rinaldi Lesmana; Levina S Pakasi; Ening Krisnuhoni
Journal:  Acta Med Indones       Date:  2012-01

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

5.  Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Damien Lucidarme; Juliette Foucher; Brigitte Le Bail; Julien Vergniol; Laurent Castera; Clotilde Duburque; Gérard Forzy; Bernard Filoche; Patrice Couzigou; Victor de Lédinghen
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

6.  Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis.

Authors:  Chia-Chi Wang; Ching-Sheng Hsu; Chun-Jen Liu; Jia-Horng Kao; Ding-Shinn Chen
Journal:  J Gastroenterol Hepatol       Date:  2007-11-19       Impact factor: 4.029

7.  Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.

Authors:  A J Czaja; H A Carpenter
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

8.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

9.  Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors.

Authors:  Man-Man Wang; Gong-Sui Wang; Feng Shen; Guang-Yu Chen; Qin Pan; Jian-Gao Fan
Journal:  Dig Dis Sci       Date:  2014-05-18       Impact factor: 3.199

10.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

Authors:  Xiaofeng Liang; Shengli Bi; Weizhong Yang; Longde Wang; Gang Cui; Fuqiang Cui; Yong Zhang; Jianhua Liu; Xiaohong Gong; Yuansheng Chen; Fuzhen Wang; Hui Zheng; Feng Wang; Jing Guo; Zhiyuan Jia; Jingchen Ma; Huaqing Wang; Huiming Luo; Li Li; Shuigao Jin; Stephen C Hadler; Yu Wang
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641

View more
  14 in total

Review 1.  Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)).

Authors:  Monica Lupsor-Platon; Radu Badea
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

3.  Fat and fiber: how the controlled attenuation parameter complements noninvasive assessment of liver fibrosis.

Authors:  Grace Lai-Hung Wong; Vincent Wai-Sun Wong
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

4.  Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease.

Authors:  Ivana Mikolasevic; Lidija Orlic; Luka Zaputovic; Sanjin Racki; Zlatko Cubranic; Kata Anic; Bosiljka Devcic; Davor Stimac
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

5.  Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.

Authors:  Thomas Karlas; Joachim Berger; Nikita Garnov; Franziska Lindner; Harald Busse; Nicolas Linder; Alexander Schaudinn; Bettina Relke; Rima Chakaroun; Michael Tröltzsch; Johannes Wiegand; Volker Keim
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

Review 6.  Non-invasive diagnosis of hepatic steatosis.

Authors:  Christiane Stern; Laurent Castera
Journal:  Hepatol Int       Date:  2016-10-25       Impact factor: 6.047

7.  Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy.

Authors:  Victor de Lédinghen; Jean-Baptiste Hiriart; Julien Vergniol; Wassil Merrouche; Pierre Bedossa; Valérie Paradis
Journal:  Dig Dis Sci       Date:  2017-06-02       Impact factor: 3.199

8.  Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.

Authors:  Patrícia Andrade; Susana Rodrigues; Eduardo Rodrigues-Pinto; Rui Gaspar; Joanne Lopes; Susana Lopes; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2016-12-23

9.  Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.

Authors:  Rui-Xu Yang; Chun-Xiu Hu; Wan-Lu Sun; Qin Pan; Feng Shen; Zhen Yang; Qing Su; Guo-Wang Xu; Jian-Gao Fan
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

10.  Effect of skin-capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease.

Authors:  Syunichiro Kimura; Kenichi Tanaka; Satoshi Oeda; Kaori Inoue; Chika Inadomi; Yoshihito Kubotsu; Wataru Yoshioka; Michiaki Okada; Hiroshi Isoda; Takuya Kuwashiro; Takumi Akiyama; Aya Kurashige; Ayaka Oshima; Mayumi Oshima; Yasue Matsumoto; Atsushi Kawaguchi; Keizo Anzai; Eisaburo Sueoka; Shinichi Aishima; Hirokazu Takahashi
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.